Literature DB >> 6291048

Abelson murine leukemia virus: structural requirements for transforming gene function.

A Srinivasan, C Y Dunn, Y Yuasa, S G Devare, E P Reddy, S A Aaronson.   

Abstract

The integrated Abelson murine leukemia virus (A-MuLV) genome cloned in bacteriophage lambda gtWES.lambda B was used to localize viral genetic sequences required for transformation. Comparison of the biological activity of cloned A-MuLV genomic and subgenomic fragments showed that subgenomic clones that lacked the 5' long terminal repeat and adjoining sequences (300 base pairs downstream of the repeat) were not biologically active. In contrast, subgenomic clones that lacked the 3' long terminal repeat and as much as 1.3 kilobase pairs of the A-MuLV cell-derived abl gene were as efficient as wild-type viral DNA in transformation. The A-MuLV-encoded polyprotein P120 and its associated protein kinase activity were detected in transformants obtained by transfection with Cla I, BamHI, and HindIII subgenomic clones. In contrast, individual transformants obtained with subgenomic Sal I clones expressed A-MuLV proteins ranging in size from 82,000 to 95,000 daltons. Each demonstrated an associated protein kinase activity. These results provide direct genetic evidence that only the proximal 40% of abl with its associated 5' helper viral sequences is required for fibroblast transformation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6291048      PMCID: PMC346933          DOI: 10.1073/pnas.79.18.5508

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene.

Authors:  M Grunstein; D S Hogness
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

2.  Structure of the Abelson murine leukemia virus genome.

Authors:  A Shields; S Goff; M Paskind; G Otto; D Baltimore
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

3.  Synthesis, surface deposition, and secretion of immunoglobulins by Abelson virus-transformed lymphosarcoma cell lines.

Authors:  E Premkumar; M Potter; P A Singer; M D Sklar
Journal:  Cell       Date:  1975-10       Impact factor: 41.582

4.  Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells.

Authors:  M Wigler; S Silverstein; L S Lee; A Pellicer; Y c Cheng; R Axel
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

5.  Protein kinase activity associated with the avian sarcoma virus src gene product.

Authors:  M S Collett; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

6.  Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells.

Authors:  O N Witte; N Rosenberg; M Paskind; A Shields; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

7.  Rapid viral induction of plasmacytomas in pristane-primed BALB-c mice.

Authors:  M Potter; M D Sklar; W P Rowe
Journal:  Science       Date:  1973-11-09       Impact factor: 47.728

8.  Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice.

Authors:  H T Abelson; L S Rabstein
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

9.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

10.  Construction and characterization of new cloning vehicles. II. A multipurpose cloning system.

Authors:  F Bolivar; R L Rodriguez; P J Greene; M C Betlach; H L Heyneker; H W Boyer; J H Crosa; S Falkow
Journal:  Gene       Date:  1977       Impact factor: 3.688

View more
  14 in total

1.  Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.

Authors:  R W Rees-Jones; S P Goff
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

2.  The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases.

Authors:  G D Kruh; R Perego; T Miki; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

3.  "Replacement" of COOH-terminal truncation of v-fms with c-fms sequences markedly reduces transformation potential.

Authors:  P J Browning; H F Bunn; A Cline; M Shuman; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 4.  Onc genes and other new targets for cancer chemotherapy.

Authors:  H Busch
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 5.  Molecular lesions in cancer.

Authors:  H Busch
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

6.  Abelson virus transformation of an interleukin 2-dependent antigen-specific T-cell line.

Authors:  W D Cook; B Fazekas de St Groth; J F Miller; H R MacDonald; R Gabathuler
Journal:  Mol Cell Biol       Date:  1987-07       Impact factor: 4.272

7.  The minimum transforming region of v-abl is the segment encoding protein-tyrosine kinase.

Authors:  R Prywes; J G Foulkes; D Baltimore
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

8.  Generation of a recombinant Moloney murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and pathogenesis in vivo.

Authors:  M H Feuerman; B R Davis; P K Pattengale; H Fan
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

9.  Conservation of function of Drosophila melanogaster abl and murine v-abl proteins in transformation of mammalian cells.

Authors:  G D Holland; M J Henkemeyer; D A Kaehler; F M Hoffmann; R Risser
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

10.  Different genes control the susceptibility of mice to Moloney or Abelson murine leukemia viruses.

Authors:  R Risser; D Kaehler; W W Lamph
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.